Vitrolife AB VITR
OMXSTO · Sweden · Health Technology
SEK 92.85-2.25 (-2.37%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Vitrolife AB (VTRLY) reports strong growth in the Americas and successful product launches, but faces regional challenges impacting overall performance.
Vitrolife Group today announces the appointment of Olivier Desmarets as Chief Operations Officer (COO), effective 1 June 2026, following the retirement of Ermanno Sironi. In this role, Olivier Desmarets will be responsible for leading the company's global operations, including Manufacturing, Labs, Supply chain & Procurement, Quality, Customer Care, IT and further strengthening operational performance across the organisation.
Vitrolife AB (publ) today announces that CEO Bronwyn Brophy O'Connor has decided to leave the company to assume a CEO role in a different area of the medtech industry. Vitrolife Group's Board has received Bronwyn's resignation and will immediately begin the recruitment process for a new CEO.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.